| __timestamp | Mesoblast Limited | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 55305000 | 242549000 |
| Thursday, January 1, 2015 | 77593000 | 245098000 |
| Friday, January 1, 2016 | 50013000 | 147600000 |
| Sunday, January 1, 2017 | 58914000 | 264600000 |
| Monday, January 1, 2018 | 65927000 | 357900000 |
| Tuesday, January 1, 2019 | 59815000 | 1182600000 |
| Wednesday, January 1, 2020 | 56188000 | 357700000 |
| Friday, January 1, 2021 | 53012000 | 540100000 |
| Saturday, January 1, 2022 | 32815000 | 322900000 |
| Sunday, January 1, 2023 | 27189000 | 408000000 |
| Monday, January 1, 2024 | 25353000 |
Unleashing the power of data
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, United Therapeutics Corporation and Mesoblast Limited have shown contrasting trends in their R&D investments.
United Therapeutics has consistently outpaced Mesoblast, with its R&D expenses peaking in 2019 at nearly four times its 2014 levels. This surge underscores the company's commitment to advancing its pipeline, particularly in the field of pulmonary arterial hypertension. In contrast, Mesoblast's R&D spending has seen a gradual decline, dropping by over 50% from 2015 to 2023. This reduction may reflect strategic shifts or financial constraints.
As we look to the future, the absence of 2024 data for United Therapeutics leaves room for speculation. Will they continue their aggressive investment, or will they pivot to a more conservative approach?
R&D Insights: How AstraZeneca PLC and Mesoblast Limited Allocate Funds
Regeneron Pharmaceuticals, Inc. or Mesoblast Limited: Who Invests More in Innovation?
R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs United Therapeutics Corporation
United Therapeutics Corporation vs Exelixis, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: United Therapeutics Corporation vs Xenon Pharmaceuticals Inc.
United Therapeutics Corporation vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Veracyte, Inc.
Incyte Corporation vs Mesoblast Limited: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Insmed Incorporated vs Mesoblast Limited
R&D Insights: How Halozyme Therapeutics, Inc. and Mesoblast Limited Allocate Funds
Research and Development: Comparing Key Metrics for Lantheus Holdings, Inc. and Mesoblast Limited
R&D Insights: How HUTCHMED (China) Limited and Mesoblast Limited Allocate Funds